Settle down guys - here are the facts !! ........
Prima has done 5 phase I studys on CVac until they found what worked. Then they completed a phase II study and are doing a second phase IIb for a ?Potency Assay? and to comply with US FDA IND. The phase III will provide ?statistical significance for US FDA and EU EMA approval?
On Abagovomab see this news
http://www.medpagetoday.com/MeetingCoverage/ASCO/26956
For Abagovomab mode of delivery(CA-125 monoclonal antibody) mimicked the previously failed phase III study of Oregovomab in 2009
See article on Oregovomab
http://jco.ascopubs.org/content/27/3/418.full
Notice the author is Dr Jonathan Berek on why Oregovomab failed. The expert call from Dr Berek on why CVac is a winner
Listen to this opinion on
http://www.investorcalendar.com/IC/CEPage.asp?ID=163542
- Forums
- ASX - By Stock
- IMM
- abagovomab vs oregovomab - facts ...
abagovomab vs oregovomab - facts ...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
29.5¢ | 29.5¢ | 28.5¢ | $738.8K | 2.546M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 75952 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 192050 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 45952 | 0.290 |
16 | 368763 | 0.285 |
34 | 1498654 | 0.280 |
6 | 185709 | 0.275 |
11 | 248398 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 192050 | 5 |
0.300 | 135983 | 5 |
0.305 | 89251 | 4 |
0.310 | 78118 | 3 |
0.315 | 44080 | 1 |
Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |